Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 20, Issue 12, Pages O1117-O1120Publisher
ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12714
Keywords
Carbapenem-resistant Enterobacteriaceae; multidrug resistance; urinary tract infection
Categories
Funding
- National Institute of Allergy And Infectious Diseases of the National Institutes of Health [UM1AI104681]
- Clinical and Translational Science Collaborative of Cleveland
- National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [UL1TR000439]
- NIH roadmap for Medical Research
- Veterans Affairs Merit Review Program
- National Institutes of Health [AI072219-05, AI063517-07]
- Geriatric Research Education and Clinical Center VISN [10]
- Research Program Committees of the Cleveland Clinic
- STERIS Corporation
Ask authors/readers for more resources
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasing global threat. Here, we describe the prevalence and impact of tigecycline use in a cohort of patients with CRKP bacteriuria nested within a multicentre, prospective study. In the 21-month study period, 260 unique patients were included. Tigecycline was given to 80 (31%) patients. The use of tigecycline during the index hospitalization was significantly associated with the subsequent development of tigecycline resistance in the same patient (OR, 6.13; 95% CI, 1.15-48.65; p0.03). In conclusion, the use of tigecycline with CRKP bacteriuria is common, and is associated with the subsequent development of tigecycline resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
